Skip to main content
LabGenomics. Co., Ltd. logo

LabGenomics. Co., Ltd. — Investor Relations & Filings

Ticker · 084650 ISIN · KR7084650001 KO Human health and social work activities
Open in API
Filings indexed 372 across all filing types
Latest filing 2026-05-20 Capital/Financing Update
Country KR South Korea
Listing KO 084650

About LabGenomics. Co., Ltd.

http://www.labgenomics.co.kr/

LabGenomics is a biotechnology company specializing in molecular diagnostics and genetic analysis. The company's core activities are structured around three primary areas: diagnostic services, Next-Generation Sequencing (NGS), and the development and manufacturing of in-vitro diagnostic (IVD) products. It provides a comprehensive range of services, including general diagnostics, sample analysis, prenatal malformation testing, and cancer genetic testing. In addition to services, LabGenomics develops and sells diagnostic kits and devices, with a focus on applications for infectious diseases. The company is actively engaged in research and development to create innovative biotechnology products and is pursuing a global expansion strategy, notably through the acquisition of CLIA-certified laboratories to enhance its service capabilities.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시)
Capital/Financing Update Classification · 85% confidence The document is a voluntary disclosure titled “증권 발행결과” (securities issuance results), detailing the issuance of the 5th unsecured convertible bonds, including amounts, dates, and listing intention. This is an announcement of a financing activity and capital structure change. Hence it falls under Capital/Financing Update (CAP).
2026-05-20 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 80% confidence The document is a formal regulatory announcement describing the company’s acquisition (repurchase) of its own convertible bonds prior to maturity, including details of issuance date, repurchase amount, purpose (put‐option exercise), funding source, and handling. This is a financing activity that changes the capital structure. It is neither a share repurchase nor dividend or interest rate notice, and contains substantive transaction details rather than just a notice of report publication. Therefore it best fits Capital/Financing Update (CAP).
2026-05-18 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서 (제 25기) 2026년 01월 01일~2026년 03월 31일” and contains detailed financial data, business overview, capital changes, share information, and other substantive interim financial statements and disclosures for the first quarter of fiscal year 2026. It is the full quarterly report itself, not a brief announcement or regulatory filing notice. Under the classification scheme, this corresponds to an Interim / Quarterly Report. Q1 2026
2026-05-15 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 88% confidence The document is a ‘주요사항보고서’ filed with the Financial Supervisory Service/Korea Exchange announcing the decision to issue convertible bonds, detailing the bond terms, interest, conversion pricing, investor, use of proceeds, collateral, etc. This is a direct financing activity (debt and capital structure update) rather than an annual report, earnings release, or internal management report. Therefore it falls under Capital/Financing Update (CAP).
2026-05-13 Korean
소속부변경
Regulatory Filings Classification · 95% confidence The document is a brief announcement about a change in the company's listing segment from '우량기업부' (Excellent Enterprise Division) to '중견기업부' (Mid-sized Enterprise Division) with a specified effective date. It does not contain financial data, management changes, voting results, or detailed reports. This type of announcement is a regulatory update about the company's stock listing status or classification on the exchange. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-30 Korean
기타경영사항(자율공시) (업무제휴계약 체결)
Regulatory Filings Classification · 85% confidence The document is a voluntary regulatory disclosure (자율공시) of a business cooperation agreement (업무제휴계약 체결) by LabGenomics. It is not an earnings release, annual or interim report, or any other specific filing type such as capital change or board appointment. It therefore falls into the general ‘Regulatory Filings’ category (RNS) as a miscellaneous corporate announcement on the exchange.
2026-04-01 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.